210 reports of this reaction
1.7% of all NEOMYCIN SULFATE reports
#10 most reported adverse reaction
THERAPEUTIC PRODUCT EFFECT INCOMPLETE is the #10 most commonly reported adverse reaction for NEOMYCIN SULFATE, manufactured by Total Resources International. There are 210 FDA adverse event reports linking NEOMYCIN SULFATE to THERAPEUTIC PRODUCT EFFECT INCOMPLETE. This represents approximately 1.7% of all 12,389 adverse event reports for this drug.
Patients taking NEOMYCIN SULFATE who experience therapeutic product effect incomplete should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THERAPEUTIC PRODUCT EFFECT INCOMPLETE is a less commonly reported adverse event for NEOMYCIN SULFATE, but still significant enough to appear in the safety profile.
In addition to therapeutic product effect incomplete, the following adverse reactions have been reported for NEOMYCIN SULFATE:
The following drugs have also been linked to therapeutic product effect incomplete in FDA adverse event reports:
THERAPEUTIC PRODUCT EFFECT INCOMPLETE has been reported as an adverse event in 210 FDA reports for NEOMYCIN SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
THERAPEUTIC PRODUCT EFFECT INCOMPLETE accounts for approximately 1.7% of all adverse event reports for NEOMYCIN SULFATE, making it a notable side effect.
If you experience therapeutic product effect incomplete while taking NEOMYCIN SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.